Medicines Australia says new NMP should be pushed back until after federal election

4 February 2022

Pharma trade group Medicines Australia is calling for the new National Medicines Policy (NMP) to be pushed back until after the federal election, expected in May.

Elizabeth de Somer, Medicines Australia chief executive, said that the NMP Review Consultation Draft, released quietly online this week, has put cost savings ahead of better health outcomes for the Australian community, and has allowed only two weeks for stakeholder feedback.

“The new National Medicines Policy is far too important to be rushed. Medicines Australia believes the government must hit the pause button and allow more detailed examination and consultation on the Draft,” Ms de Somer said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK